摘要
目的:比较富马酸替诺福韦二吡呋酯(TDF)+拉米夫定(3TC)+依非韦伦(EFV)方案与复合制剂依非米替治疗人类免疫缺陷病毒(HIV)感染的效果。方法:选择2022年8月-2024年1月赣州市第五人民医院收治的78例HIV感染患者,采用随机分组法分为观察组和对照组,各39例。对照组接受TDF+3TC+EFV治疗,观察组接受复合制剂依非米替治疗,比较两组的临床疗效、HIV载量、T淋巴细胞计数(CD4^(+)、CD8^(+))、生化指标(Hb、BUN、Scr)水平、MoCA评分、SF-36评分、用药依从性及不良反应发生率。结果:观察组治疗有效率高于对照组,差异有统计学意义(P<0.05);治疗后,两组HIV载量、CD8^(+)、BUN、Scr低于治疗前,CD4^(+)、Hb高于治疗前,且观察组CD4^(+)、Hb高于对照组,HIV载量、CD8^(+)、BUN、Scr低于对照组,差异有统计学意义(P<0.05)。治疗后,两组MoCA评分、SF-36各维度评分高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组Morisky服药依从性量表(MMAS-8)评分高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:与TDF+3TC+EFV方案相比,复合制剂依非米替治疗HIV感染患者效果更优,有助于降低不良反应发生率。
Objective:To compare the effects of Tenofovir Disoproxil Fumarate(TDF)+Lamivudine(3TC)+Efavirenz(EFV)regimen and compound preparation Efavirenz,Lamivudine and Tenofovir Disoproxil Fumarate in the treatment of human immunodeficiency virus(HIV)infection.Method:Seventy-eight patients with HIV infection admitted to Ganzhou Fifth People's Hospital from August 2022 to January 2024 were selected and randomly divided into the observation group and the control group,with 39 cases in each group.The control group was treated with TDF+3TC+EFV,while the observation group was treated with compound preparation Efavirenz,Lamivudine and Tenofovir Disoproxil Fumarate.Comparisons were made between the two groups on clinical efficacy,HIV load,T lymphocyte count(CD4^(+),CD8^(+)),levels of biochemical indexes(Hb,BUN and Scr),MoCA score,SF-36 score,medication adherence,and incidence of adverse reactions.Result:The effective rate of treatment in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,the HIV load,CD8^(+),+BUN and Scr in both groups were lower than those before treatment,while CD4 and Hb were+higher than those before treatment;moreover,CD4 and Hb in the observation group were higher than those in the control group,HIV load,CD8^(+),BUN and Scr were all lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the MoCA scores and the scores of each dimension of SF-36 in both groups were higher than those before treatment,and the scores in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).The score of the Morisky medication adherence scale-8(MMAS-8)in the observation group was higher than that in the control group,the incidence of adverse reactions was lower than that in the control group,the differences were statistically significant(P<0.05).Conclusion:Compared with the TDF+3TC+EFV regimen,compound preparation Efavirenz,Lamivudine and Tenofovir Disoproxil Fumarate is more effective to treat HIV infection and can help to reduce the incidence of adverse reactions.
作者
卓倩
敖建
钟丽娜
杨雨婷
ZHUO Qian;AO Jian;ZHONG Lina;YANG Yuting(Pharmacy Department,Ganzhou Fifth People's Hospital,Ganzhou 341000,China;不详)
出处
《中国医学创新》
2025年第21期114-118,共5页
Medical Innovation of China
基金
赣州市指导性科技计划项目(GZ2024ZSF322)。
关键词
人类免疫缺陷病毒
富马酸替诺福韦二吡呋酯
拉米夫定
依非韦伦
依非米替
用药
依从性
Human immunodeficiency virus
Tenofovir Disoproxil Fumarate
Lamivudine
Efavirenz Efavirenz
Lamivudine and Tenofovir Disoproxil Fumarate
Medication adherence
